- Hardcover: 336 pages
- Publisher: Kaplan Trade; 1 edition (31 July 2011)
- Language English
- ISBN-10: 1607146304
- ISBN-13: 978-1607146308
- Product Dimensions: 23.1 x 15.7 x 3.3 cm
- Amazon Bestsellers Rank: 1,652,038 in Books (See Top 100 in Books)
All the Justice Money Can Buy: Corporate Greed on Trial
and over one million other books are available for Amazon Kindle .
Learn more
| ||||||||||||||||||||
Did you know you can trade in your old books for an Amazon.co.uk Gift Card to spend on the things you want? Visit the Amazon.co.uk Trade-In Store for more details. |
Product details |
More About the Author
Product Description
Product Description
Mark Lanier knew he was facing an opponent willing to break every rule in the book, and each part of his case had to go just right for him to win. He had done it twice before. Could he do it again? All the Justice Money Can Buy is the true-life story of a courtroom showdown between the man many consider the best trial lawyer of his generation and one of the nation s richest and most-respected corporations. Journalist Snigdha Prakash is embedded with the plaintiffs team for the seven-week trial, and takes us into the trenches of the tough and dirty battle between corporate interests and the individual that plays out in the courts. From early mornings when Lanier works in his hotel suite, to the daily post-mortems after court, and late nights in the plaintiffs war room, Prakash shadows Lanier and his team. With its bird s-eye view of the strategic thinking and meticulous planning that undergird Lanier s seemingly unrehearsed performances in court, and of the well-oiled machine of lawyers and assistants that backs his every move, All the Justice Money Can Buy is a fast-paced, often funny journey behind the front-lines of a high-stakes, 21st century legal trial. Along the way, Prakash renders a piercing portrait of the challenges that await those who would take on corporate interests. Part corporate expose´ and part legal thriller, All the Justice Money Can Buy is a gripping and topical read for our scandal-plagued times.
Inside This Book
(Learn More)
Tag this product(What's this?)Think of a tag as a keyword or label you consider is strongly related to this product.
Tags will help all customers organise and find favourite items. |
Customer Reviews
There are no customer reviews yet on Amazon.co.uk.
5 star
4 star
3 star
2 star
1 star
Most Helpful Customer Reviews on Amazon.com (beta)
Amazon.com:
15 reviews
10 of 10 people found the following review helpful
A fascinating and important read
10 Jun 2011
Format:Hardcover
This book is an excellent read. Written in clean, fresh prose, it compellingly tells its disturbing tale in the form of a real-life courtroom drama. I read it within 24 hours--couldn't put it down. Merck's convoluted attempts to deny culpability for the Vioxx-heart attack connection are laid out plainly and clearly. In many ways, the book gets to the heart of one of the many flaws in our health-care system: When money talks, seemingly decent people will shut their eyes and ears. It also paints a blatant picture of how individual human beings can become almost irrelevant to their own story, once the wheels of "justice" start rolling. It provides a fascinating, complex characterization of the lead prosecutor, as well as thoughtful descriptions of those around him. Throughout it, the author's charming but unobtrusive voice renders the events as immediately as if she were sitting ringside at a championship fight. Highly recommended.
4 of 4 people found the following review helpful
Both Inspiring and Disillusioning -
25 Aug 2011
Format:Hardcover
This is the true story of a legal battle (the trial itself took 7 weeks) between a respected corporation (Merck) and a man man consider the best trial lawyer (Mark Lanier) over whether Merck had adequately warned doctors and patients about heart attack risks associated with its Vioxx painkiller. The story begins by relating how Vioxx allegedly injured two individuals and killed a third, how those initially involved sought legal help, and then thousands of similar cases were consolidated from among the almost 20 million that had used it before Merck pulled the drug from the market. (A senior FDA scientist estimated Vioxx caused 88,000 - 140,000 serious cases, with almost half fatal.)
Merck created a $675 million legal fund in 2004, and by the end of 2006 had spent all of that plus an additional $110 million. By the end of 2006 only 13 cases had been tried (first began in 2000), with Merck winning eight, two ending in mistrials, and the plaintiffs winning three. Merck then appealed all the cases it lost, and attempted to consolidate the remaining cases in federal court - easier to defend. Plaintiffs, however, managed to consolidate the majority of cases into a N.J. state court trial. That trial is the focus of the book.
Lead attorney Lanier recognized he had to explain the science involved in simple terms, and that doing so required 25 - 30 such 'mini-lessons.' Lanier had made himself a student of such teaching, and believed only three such concepts/day could be absorbed and retained by jurors. (The federal trials were limited to three weeks - a length Lanier believed was insufficient for the complexity involved and teaching required.) Lanier's exhaustive preparations included surveying the Atlantic City juror pool to develop a 170-item jury questionnaire to help in jury selection, requesting and reviewing some million pages of internal Merck documents, assembling a mock jury that was questioned each day to determine reactions, reviewing past testimony of the major witnesses, and considerable effort devoted to how he would visualize his story using PowerPoint and displays. Author Prakash also relates the gamesmanship underlying legal objections during the trial, and why 'top of the class' lawyers are not necessarily best in the courtroom (written skills dominate class rankings, oral skills in the courtroom).
Ultimately most of the plaintiffs won, and Merck paid out $4.85 billion that was allocated among 50,000 claimants. Typical individual recoveries ranged from $100,000 to $375,000, less about half for legal expenses and fees.
Bottom-Line: Reading "All the Justice Money Can Buy" was inspiring - learning the skills and effort put into the case by Mark Lanier and his associates. The book was also disillusioning - learning how Merck had deliberately put patient safety aside to maximize earnings, and then tried throughout the trial to cover this up.
Merck created a $675 million legal fund in 2004, and by the end of 2006 had spent all of that plus an additional $110 million. By the end of 2006 only 13 cases had been tried (first began in 2000), with Merck winning eight, two ending in mistrials, and the plaintiffs winning three. Merck then appealed all the cases it lost, and attempted to consolidate the remaining cases in federal court - easier to defend. Plaintiffs, however, managed to consolidate the majority of cases into a N.J. state court trial. That trial is the focus of the book.
Lead attorney Lanier recognized he had to explain the science involved in simple terms, and that doing so required 25 - 30 such 'mini-lessons.' Lanier had made himself a student of such teaching, and believed only three such concepts/day could be absorbed and retained by jurors. (The federal trials were limited to three weeks - a length Lanier believed was insufficient for the complexity involved and teaching required.) Lanier's exhaustive preparations included surveying the Atlantic City juror pool to develop a 170-item jury questionnaire to help in jury selection, requesting and reviewing some million pages of internal Merck documents, assembling a mock jury that was questioned each day to determine reactions, reviewing past testimony of the major witnesses, and considerable effort devoted to how he would visualize his story using PowerPoint and displays. Author Prakash also relates the gamesmanship underlying legal objections during the trial, and why 'top of the class' lawyers are not necessarily best in the courtroom (written skills dominate class rankings, oral skills in the courtroom).
Ultimately most of the plaintiffs won, and Merck paid out $4.85 billion that was allocated among 50,000 claimants. Typical individual recoveries ranged from $100,000 to $375,000, less about half for legal expenses and fees.
Bottom-Line: Reading "All the Justice Money Can Buy" was inspiring - learning the skills and effort put into the case by Mark Lanier and his associates. The book was also disillusioning - learning how Merck had deliberately put patient safety aside to maximize earnings, and then tried throughout the trial to cover this up.
3 of 3 people found the following review helpful
Trial Theater
24 July 2011
Format:Hardcover|Amazon Verified Purchase
In "All the Justice Money Can Buy: Corporate Greed on Trial," author Snigdha Prakash provides a unique view behind the scenes as the plaintiffs' legal team prepares and goes to battle. It is an engaging and sometimes humorous story of court room theatrics with a significant and painful dose of reality. The book is provocative and will provide book clubs and discussion groups a great deal to talk about. Five stars!
Were these reviews helpful?
Let us know
Listmania!
Look for similar items by category
- Books > Business, Finance & Law > Biographies & Histories > Business & Economic History
- Books > Business, Finance & Law > Biographies & Histories > Company Histories
- Books > Business, Finance & Law > Law
- Books > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Ancillary Services > Pharmacy - Dispensing
- Books > Health, Family & Lifestyle > Medical & Healthcare Practitioners > Other Branches of Medicine > Pharmacology
- Books > Science & Nature > Medicine > Medical Sciences A-Z > Pharmacology
- Books > Scientific, Technical & Medical
Look for similar items by subject
Feedback
- Would you like to update product info or give feedback on images?
- I am the Author, and I want to comment on my book.
- I am the Publisher, and I want to comment on this book.
|
